{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:51:56Z","timestamp":1747356716024,"version":"3.37.3"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Diabetes"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1111\/pedi.12358","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T04:48:43Z","timestamp":1453178923000},"page":"642-649","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec\/insulin aspart in children, adolescents, and adults with type 1 diabetes"],"prefix":"10.1155","volume":"17","author":[{"given":"Torben","family":"Biester","sequence":"first","affiliation":[{"name":"Diabetes Centre for Children and Adolescents; Kinder- und Jugendkrankenhaus AUF DER BULT; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Danne","sequence":"additional","affiliation":[{"name":"Diabetes Centre for Children and Adolescents; Kinder- und Jugendkrankenhaus AUF DER BULT; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Bl\u00e4sig","sequence":"additional","affiliation":[{"name":"Diabetes Centre for Children and Adolescents; Kinder- und Jugendkrankenhaus AUF DER BULT; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Remus","sequence":"additional","affiliation":[{"name":"Diabetes Centre for Children and Adolescents; Kinder- und Jugendkrankenhaus AUF DER BULT; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e4rbel","family":"Aschemeier","sequence":"additional","affiliation":[{"name":"Diabetes Centre for Children and Adolescents; Kinder- und Jugendkrankenhaus AUF DER BULT; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Kordonouri","sequence":"additional","affiliation":[{"name":"Diabetes Centre for Children and Adolescents; Kinder- und Jugendkrankenhaus AUF DER BULT; Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Bardtrum","sequence":"additional","affiliation":[{"name":"Biostatistics, Novo Nordisk A\/S; S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Haahr","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology; Novo Nordisk A\/S; S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,18]]},"reference":[{"key":"10.1111\/pedi.12358-BIB0001|pedi12358-cit-0001","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2337\/dc14-1140","article-title":"Type 1 diabetes through the life span: a position statement of the American Diabetes Association","volume":"37","author":"Chiang","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1111\/pedi.12358-BIB0002|pedi12358-cit-0002","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1399-5448.2008.00479.x","article-title":"State of the world's children with diabetes","volume":"10","author":"Daneman","year":"2009","journal-title":"Pediatr Diabetes"},{"key":"10.1111\/pedi.12358-BIB0003|pedi12358-cit-0003","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1542\/peds.113.3.e221","article-title":"Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy","volume":"113","author":"Burdick","year":"2004","journal-title":"Pediatrics"},{"key":"10.1111\/pedi.12358-BIB0004|pedi12358-cit-0004","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/dc09-1348","article-title":"Correlates of insulin injection omission","volume":"33","author":"Peyrot","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1111\/pedi.12358-BIB0005|pedi12358-cit-0005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/pedi.12190","article-title":"Assessment and monitoring of glycemic control in children and adolescents with diabetes","volume":"S20","author":"Rewers","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"10.1111\/pedi.12358-BIB0006|pedi12358-cit-0006","unstructured":"National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management 2015 https:\/\/www.nice.org.uk\/guidance\/ng18"},{"key":"10.1111\/pedi.12358-BIB0007|pedi12358-cit-0007","unstructured":"National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management 2015 https:\/\/www.nice.org.uk\/guidance\/ng17"},{"key":"10.1111\/pedi.12358-BIB0008|pedi12358-cit-0008","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/pedi.12165","article-title":"ISPAD Clinical Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic hyperosmolar state","volume":"15","author":"Wolfsdorf","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"10.1111\/pedi.12358-BIB0009|pedi12358-cit-0009","doi-asserted-by":"crossref","first-page":"2","DOI":"10.17925\/USE.2006.00.1.2f","article-title":"Hypoglycemia - the major barrier to good glycemic control","volume":"1","author":"Davis","year":"2006","journal-title":"US Endocrine Rev"},{"key":"10.1111\/pedi.12358-BIB0010|pedi12358-cit-0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2431-10-50","article-title":"Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review","volume":"10","author":"Barnard","year":"2010","journal-title":"BMC Pediatr"},{"key":"10.1111\/pedi.12358-BIB0011|pedi12358-cit-0011","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1007\/s11095-014-1614-x","article-title":"Investigation of the physico-chemical properties that enable co-formulation of basal insulin degludec with fast-acting insulin aspart","volume":"32","author":"Havelund","year":"2015","journal-title":"Pharm Res"},{"key":"10.1111\/pedi.12358-BIB0012|pedi12358-cit-0012","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s13300-014-0070-2","article-title":"Distinct prandial and basal glucose-lowering effects of insulin degludec\/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus","volume":"5","author":"Heise","year":"2014","journal-title":"Diabetes Ther"},{"key":"10.1111\/pedi.12358-BIB0013|pedi12358-cit-0013","unstructured":"Aug 2015 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002499\/WC500139011.pdf"},{"key":"10.1111\/pedi.12358-BIB0014|pedi12358-cit-0014","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.2337\/dc11-2503","article-title":"Insulin degludec\/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial","volume":"35","author":"Hirsch","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1111\/pedi.12358-BIB0015|pedi12358-cit-0015","unstructured":"January 2001 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002926.pdf"},{"key":"10.1111\/pedi.12358-BIB0016|pedi12358-cit-0016","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","article-title":"Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia","volume":"28","author":"Workgroup on Hypoglycemia, American Diabetes Association","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1111\/pedi.12358-BIB0017|pedi12358-cit-0017","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/dom.12463","article-title":"Insulin degludec\/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus","volume":"17","author":"Heise","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/pedi.12358-BIB0018|pedi12358-cit-0018","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40266-015-0272-y","article-title":"The distinct prandial and basal pharmacodynamics of IDegAsp observed in younger adults are preserved in elderly subjects with type 1 diabetes","volume":"32","author":"Brunner","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1111\/pedi.12358-BIB0019|pedi12358-cit-0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/pedi.12116","article-title":"Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes","volume":"15","author":"Biester","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"10.1111\/pedi.12358-BIB0020|pedi12358-cit-0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/pedi.12263","article-title":"Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes","volume":"16","author":"Thalange","year":"2015","journal-title":"Pediatr Diabetes"},{"key":"10.1111\/pedi.12358-BIB0021|pedi12358-cit-0021","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","article-title":"A review of the pharmacological properties of insulin degludec and their clinical relevance","volume":"53","author":"Haahr","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/pedi.12358-BIB0022|pedi12358-cit-0022","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jpeds.2010.08.046","article-title":"Pubertal changes of insulin sensitivity, acute insulin response, and beta-cell function in overweight Latino youth","volume":"158","author":"Kelly","year":"2011","journal-title":"J Pediatr"},{"key":"10.1111\/pedi.12358-BIB0023|pedi12358-cit-0023","unstructured":"Danne T Biester T Fath M"},{"key":"10.1111\/pedi.12358-BIB0024|pedi12358-cit-0024","unstructured":"US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research. General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products. Guidance for Industry December 2014 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM425885.pdf"},{"key":"10.1111\/pedi.12358-BIB0025|pedi12358-cit-0025","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/pedi.12358-BIB0026|pedi12358-cit-0026","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/diacare.12.9.641","article-title":"Clinical significance of insulin antibodies in insulin-treated diabetic patients","volume":"12","author":"Van Haeften","year":"1989","journal-title":"Diabetes Care"},{"key":"10.1111\/pedi.12358-BIB0027|pedi12358-cit-0027","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1530\/eje.1.02021","article-title":"Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes","volume":"153","author":"Chen","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/pedi.12358-BIB0028|pedi12358-cit-0028","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1210\/er.2007-0002","article-title":"Immunological responses to exogenous insulin","volume":"28","author":"Fineberg","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1111\/pedi.12358-BIB0029|pedi12358-cit-0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/pedi.12184","article-title":"Insulin treatment in children and adolescents with diabetes","volume":"15","author":"Danne","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"10.1111\/pedi.12358-BIB0030|pedi12358-cit-0030","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1210\/jc.2012-3249","article-title":"Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension","volume":"98","author":"Mathieu","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pediatric Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpedi.12358","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/pedi.12358\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:08:46Z","timestamp":1671818926000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pedi.12358"}},"subtitle":["PK\/PD of IDegAsp in pediatric T1DM"],"short-title":[],"issued":{"date-parts":[[2016,1,18]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,12]]}},"URL":"https:\/\/doi.org\/10.1111\/pedi.12358","archive":["Portico"],"relation":{},"ISSN":["1399-543X"],"issn-type":[{"type":"print","value":"1399-543X"}],"subject":[],"published":{"date-parts":[[2016,1,18]]}}}